Anti-VEGF Continuation Wanes After 3-6 Years for Patients with nAMD

Video

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

Real-world data suggest anti-VEGF injections generally slow among patients being treated for neovascular age-related macular degeneration (nAMD) in years 3-6 of therapy.

The findings, derived from an assessment of the Intelligent Research in Sight (IRIS) Registry database, show that slowed regimens during this time—as well as an increased rate of therapy discontinuation altogether—could implicate greater long-term risks of vision loss for patients with nAMD.

Presented at the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting this weekend by Theodore Leng, MD, MS, Associate Professor of Ophthalmology at Stanford University, the trial provided a snapshot of treatment continuation among patients with nAMD prescribed any of 3 prominent anti-VEGF treatments: aflibercept, bevacizumab, and ranibizumab.

In an interview with HCPLive during ASRS 2021, Leng discussed the study findings and their benefit for interpreting long-term nAMD patient treatment tendencies.

“You’re right about this being a pivotal time in the use of these agents,” Leng said. “We’ve had them around since the 2005 time frame—at least 10 years experience with these different agents. And we’ve really come into our own as far as figuring out the best treatment modalities, whether that’s monthly, PRN (pro re nata), or treat and extend, or some combination of those.”

Leng also highlighted the substantial utility of the US-based IRIS database, and other interesting outcomes associated with long-term visual acuity from his team’s research.

The study, “Long-term Experience With Intravitreal Anti-VEGF Treatment in Patients With nAMD: Analysis of IRIS® (Intelligent Research in Sight) Registry Database,” was presented at ASRS 2021.

Recent Videos
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.